BNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Burning Rock Biotech Ltd (BNR) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows no clear technical signals for entry, lacks positive catalysts, and has weak financial performance. Holding or exploring other opportunities may be more prudent.
The MACD is positive but contracting, RSI is neutral at 40.098, and moving averages are converging. The stock is trading near its pivot level of 18.801, with support at 16.077 and resistance at 21.524. No strong trend or breakout signal is evident.
Gross margin increased by 9.96% YoY in Q4 2025, indicating some operational efficiency improvements.
Net income dropped significantly by -81.07% YoY, and EPS fell by -81.01% YoY. No recent news or significant insider/hedge fund activity. Analysts have downgraded similar companies in the sector, reflecting a cautious outlook.
In Q4 2025, revenue increased slightly by 0.23% YoY, but net income and EPS dropped significantly. Gross margin improved to 78.03%, but overall financial performance remains weak.
No direct analyst rating for BNR, but similar companies in the sector have been downgraded, indicating a cautious sentiment.
